DDR2

discoidin domain receptor tyrosine kinase 2

Explore in graph →CI-GENE-00043057HGNC:2731 ENSG00000162733 NCBI 4921 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (9)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–9 of 9 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
DDR2 G253C1
Dasatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted

Cohorts

Alteration frequency by cohort (95)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

gdcObserved95 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
APOLLO1: Proteogenomic characterization of lung adenocarcinoma APOLLO-LUAD	Lung Adenocarcinoma

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
· Cancer Discov · 2011 · PMID 22328973 · validated civic_curation pubmed

DDR2 G505S1
Dasatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID267 In 3T3 fibroblasts expressing the G505S mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic

DDR2 G774V1
Dasatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	3	accepted	EID268 Ba/F3 cells expressing the G774V mutation were sensitive to the tyrosine kinase inhibitor dasatinib while wild-type expressing cells were not, as measured in a proliferation assay. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic

DDR2 High expression1
Dasatinib	Malignant Gastric Neoplasm	Predictive	D	Supports Sensitivity Response	2	submitted	EID9853 Expression analysis of multiple cohorts of gastric cancer patients in addition to in vivo selected metastatic cell lines, identified DDR2 as the driver of peritoneal dissemination. Within the Singapor… (full text at CIViC) PMID 26934957 · Kurashige et al., 2016 · Open in CIViC	civic

DDR2 I638F1
Dasatinib	Lung Squamous Cell Carcinoma	Predictive	D	Supports Sensitivity Response	4	accepted	EID269 The NCI-H2286 lung squamous cell carcinoma cell line, containing the DDR2 I638F mutation was shown to be sensitive (IC50 139nm) to dasatinib in-vitro. Dasatanib sensitivity was demonstrated in-vivo us… (full text at CIViC) PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic

DDR2 L239R1
Dasatinib	Lung Adenosquamous CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID270 The HCC-366 lung adenosquamous carcinoma cell line, containing the DDR2 L239R mutation was shown to be sensitive (IC50 140nm) to dasatinib in-vitro. The authors were unable to establish tumors using t… (full text at CIViC) PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic

DDR2 L63V1
Dasatinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	4	accepted	EID271 In 3T3 fibroblasts expressing the L63V mutation have to be sensitive to the tyrosine kinase inhibitor dasatinib. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic

DDR2 Overexpression1
Dasatinib	Head and Neck Carcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID9854 Validating predominant overexpression of DDR2 in 554 head and neck squamous cell carcinoma (HNSCC) patients indicated the potentiality of utilizing dasatinib as a DDR2 inhibitor. From these patients, … (full text at CIViC) PMID 27434411 · von Mässenhausen et al., 2016 · Open in CIViC	civic

DDR2 S768R1
Dasatinib + ErlotinibCombination	Lung Squamous Cell Carcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID272 In a patient expressing a DDR2 S768R mutation, treatment with dasatinib plus erlotinib acheived a partial response. PMID 22328973 · Hammerman et al., 2011 · Open in CIViC	civic